Extreme LDL-C concentration is associated with increased cardiovascular disease in women with homozygous familial hypercholesterolemia

被引:0
|
作者
Paquette, Martine [1 ]
Ruel, Isabelle [2 ]
Guay, Simon-Pierre [1 ,3 ]
Al-Baldawi, Zobaida [4 ]
Brisson, Diane [5 ]
Gaudet, Daniel [5 ]
Couture, Patrick [6 ]
Bergeron, Jean [6 ]
Hegele, Robert A. [7 ,8 ,9 ]
Francis, Gordon A. [10 ,11 ]
Sherman, Mark H. [12 ]
Mcpherson, Ruth [13 ,14 ]
Ransom, Thomas [15 ]
Brunham, Liam R. [10 ,11 ]
Mancini, John [16 ]
Mccrindle, Brian W. [17 ]
Latan, Lulia
Genest, Jacques [2 ]
Baass, Alexis [1 ,18 ,19 ]
机构
[1] Montreal Clin Res Inst, Lipids Nutr & Cardiovasc Prevent Clin, 110 Ave Des Pins Ouest, Montreal, PQ H2W1R7, Canada
[2] Res Inst McGill Univ Hlth Ctr, Montreal, PQ, Canada
[3] Univ Montreal, Dept Med, Div Endocrinol, Montreal, PQ, Canada
[4] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada
[5] ECOGENE 21 Clin & Translat Res Ctr, Chicoutimi, PQ, Canada
[6] Univ Laval, CHU Quebec, Dept Specialized Med, Lipid Clin, Quebec City, PQ, Canada
[7] Western Univ, Dept Med, Schulich Sch Med, London, ON, Canada
[8] Western Univ, Schulich Sch Med, Dept Biochem, London, ON, Canada
[9] Western Univ, Robarts Res Inst, London, ON, Canada
[10] Univ British Columbia, Ctr Heart Lung Innovat, Providence Hlth Care Res Inst, Vancouver, BC, Canada
[11] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[12] McGill Univ, Hlth Ctr, Dept Endocrinol, Montreal, PQ, Canada
[13] Univ Ottawa, Heart Inst, Lipid Clin, Ottawa, ON, Canada
[14] Univ Ottawa, Heart Inst, Atherogenom Lab, Ottawa, ON, Canada
[15] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada
[16] Univ British Columbia, Ctr Cardiovasc Innovat, Vancouver, BC, Canada
[17] Univ Toronto, Hosp Sick Children, Labatt Family Heart Ctr, Dept Pediat, Toronto, ON, Canada
[18] McGill Univ, Div Expt Med, Dept Med, Montreal, PQ, Canada
[19] McGill Univ, Dept Med, Div Med Biochem, Montreal, PQ, Canada
关键词
Homozygous; Familial hypercholesterolemia; LDL-C; Cardiovascular; Risk factors; PREVALENCE;
D O I
10.1016/j.jacl.2024.10.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is arare genetic disease of low- density lipoprotein cholesterol (LDL-C) metabolism. Despite the devastating effect of this disease on atherosclerotic cardiovascular health, the disease phenotype and severity are more heterogeneous than previously thought. The predictors of atherosclerotic cardiovascular disease (ASCVD) in HoFH patients have never been systematically studied. OBJECTIVE: To investigate the univariate and multivariate predictors of ASCVD in HoFH patients. METHODS: Patients from the Canadian HoFH Registry were included in the present retrospective longitudinal study. Data for these patients were collected using a standardized questionnaire between 2019 and 2022 in 19 academic sites across Canada. Predictors of ASCVD were evaluated using Cox proportional hazards models. RESULTS: Among 48 HoFH patients, 26 (54%) of them had at least 1 ASCVD event. The average age at baseline was 19 +/- 15 years and women represented 56% of the cohort. The independent predictors of ASCVD events were male sex (HR 2.57 [1.13-5.84]), diabetes (HR 16.22 [3.38-77.97]), and LDL-C above the median of 14.45 mmol/L (559 mg/dL) (HR 3.10 [1.24-7.76]). When performing subgroup analysis according to sex, the presence of LDL-C above the median was associated with a significantly higher probability of ASCVD (88% vs 43%, P = .005) in women, but not in men (100% at age 40 in both groups, P = .98). CONCLUSION: This study reported for the first time the univariate and multivariate predictors of ASCVD in HoFH patients. We demonstrate that predictors of ASCVD in HoFH differ in males and females with respect to LDL-C levels. (c) 2024 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:105 / 113
页数:9
相关论文
共 50 条
  • [41] BURDEN OF CARDIOVASCULAR DISEASE (CVD) FOR PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH) OR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) AND THE IMPACT OF REDUCING LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LOWERING IN LATIN AMERICAN COUNTRIES
    Vianna, D.
    Habib, M.
    Villa, G.
    Qian, Y.
    Xiang, P.
    Bahia, L. R.
    Alves, F. P.
    Alva, M. E.
    Ruiz Morales, A.
    Verdejo Paris, J.
    VALUE IN HEALTH, 2017, 20 (09) : A611 - A611
  • [42] LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes
    Santos, Raul D.
    Cuchel, Marina
    CIRCULATION, 2024, 149 (05) : 363 - 366
  • [43] The Role of Cumulative LDL Cholesterol in Cardiovascular Disease Development in Patients with Familial Hypercholesterolemia
    Korneva, Victoria
    Kuznetsova, Tatyana
    Julius, Ulrich
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (01):
  • [44] HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) MONITORING FOR 15 YEARS
    Goetz, Eglantine
    Saheb, Samir
    Djahel, Chanez
    Gallo, Antonio
    Gbaguidi, Destino
    Mongenot, Manon
    Chalopin, Sarah
    Sakka, Mehdi
    Carrie, Alain
    Bluteau, Olivier
    Marignan, Lionel
    Bittar, Randa
    Bonnefont-Rousselot, Dominique
    ATHEROSCLEROSIS, 2024, 395
  • [45] Disruption of ldlr causes increased LDL-c and vascular lipid accumulation in a zebrafish model of hypercholesterolemia
    O'Hare, Elizabeth A.
    Wang, Xiaochun
    Montasser, May E.
    Chang, Yen-Pei C.
    Mitchell, Braxton D.
    Zaghloul, Norann A.
    JOURNAL OF LIPID RESEARCH, 2014, 55 (11) : 2242 - 2253
  • [46] Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
    Henry N. Ginsberg
    Daniel J. Rader
    Frederick J. Raal
    John R. Guyton
    Marie T. Baccara-Dinet
    Christelle Lorenzato
    Robert Pordy
    Erik Stroes
    Cardiovascular Drugs and Therapy, 2016, 30 : 473 - 483
  • [47] Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
    Ginsberg, Henry N.
    Rader, Daniel J.
    Raal, Frederick J.
    Guyton, John R.
    Baccara-Dinet, Marie T.
    Lorenzato, Christelle
    Pordy, Robert
    Stroes, Erik
    CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (05) : 473 - 483
  • [48] SMALL DENSE LDL-C DISCORDANCE IS ASSOCIATED WITH HIGHER CARDIOVASCULAR RISK
    Zubiran, Rafael
    Sampson, Maureen
    Remaley, Alan
    ATHEROSCLEROSIS, 2024, 399 : 26 - 26
  • [49] HYPERHOMOCYSTEINEMIA AND CHANGES IN FIBRINOLYTIC PARAMETERS ARE ASSOCIATED WITH CARDIOVASCULAR-DISEASE IN MEN AND WOMEN WITH FAMILIAL HYPERCHOLESTEROLEMIA
    WITTEKOEK, ME
    MINNEMA, MC
    KNIPSCHEER, HC
    BULLER, HR
    KASTELEIN, JJP
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 951 - 951
  • [50] Mipomersen, a First-in-Class Apo-B Synthesis Inhibitor, Lowers LDL-C in Patients With Homozygous Familial Hypercholesterolemia: Results of a Phase III Study
    Real, Frederick
    Santos, Raul
    Niu, Dau-Ming
    Lachmann, Robin H.
    Gaudet, Daniel
    Le Tan, Ju
    Cromwell, William C.
    Marais, David
    Tribble, Diane L.
    Flaim, Joann D.
    Crooke, Stanley T.
    CIRCULATION, 2009, 120 (18) : S475 - S476